Pieris Pharmaceuticals (PIRS) Short Interest Ratio & Short Volume → Wall Street legend who predicted 2021 tech crash issues new warning (From Chaikin Analytics) (Ad) Free PIRS Stock Alerts $11.37 +0.15 (+1.34%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Pieris Pharmaceuticals Short Interest DataCurrent Short Volume12,800 sharesPrevious Short Volume300 sharesChange Vs. Previous Month+4,166.67%Dollar Volume Sold Short$149,888.00Short Interest Ratio / Days to Cover0.9Last Record DateApril 30, 2024Outstanding Shares1,240,000 sharesFloat Size1,140,000 sharesShort Percent of Float1.12%Today's Trading Volume8,246 sharesAverage Trading Volume10,940 sharesToday's Volume Vs. Average75% Short Selling Pieris Pharmaceuticals ? Sign up to receive the latest short interest report for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPIRS Short Interest Over TimePIRS Days to Cover Over TimePIRS Percentage of Float Shorted Over Time Ad Chaikin AnalyticsThis Wall Street stock prediction just went viralPeople around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch just the first 5 minutes of his new prediction Pieris Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202412,800 shares $149,888.00 +4,166.7%1.1%0.9 $11.71 4/15/2024300 shares $4,080.00 -99.8%0.0%0 $13.60 3/31/2024134,100 shares $24,567.12 +222.4%N/A0.2 $0.18 3/15/202441,600 shares $7,030.40 -41.2%N/A0.1 $0.17 2/29/202470,700 shares $11,672.57 +6.8%N/A0.1 $0.17 2/15/202466,200 shares $10,505.94 -69.1%N/A0.1 $0.16 Get the Latest News and Ratings for PIRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024214,500 shares $39,661.05 +31.1%N/A0.4 $0.18 1/15/2024163,600 shares $29,268.04 +22.6%N/A0.3 $0.18 12/31/2023133,400 shares $24,278.80 -17.5%N/A0.2 $0.18 12/15/2023161,600 shares $26,680.16 +145.6%N/A0.3 $0.17 11/30/202365,800 shares $13,442.94 -3.1%N/A0.1 $0.20 11/15/202367,900 shares $15,725.64 -63.5%N/A0.1 $0.23 10/31/2023186,100 shares $44,273.19 -26.7%N/A0.1 $0.24 10/15/2023253,900 shares $72,006.04 -55.7%N/A0.1 $0.28 9/30/2023573,500 shares $170,903.00 -5.2%N/A0.2 $0.30 9/15/2023605,200 shares $188,822.40 -57.4%N/A0.2 $0.31 8/31/20231,420,000 shares $481,806.00 +35.2%N/A0.4 $0.34 8/15/20231,050,000 shares $252,420.00 -28.6%N/A0.3 $0.24 7/31/20231,470,000 shares $324,870.00 +293.8%N/A0.5 $0.22 7/15/2023373,300 shares $72,793.50 -84.6%N/A0.1 $0.20 6/30/20232,420,000 shares $400,510.00 +32.2%N/A1.6 $0.17 6/15/20231,830,000 shares $1.63 million -1.1%N/A1.4 $0.89 5/31/20231,850,000 shares $1.57 million +0.5%N/A2.6 $0.85 5/15/20231,840,000 shares $1.59 million -1.1%N/A3 $0.86 4/30/20231,860,000 shares $1.41 million +1.6%N/A5.4 $0.76 4/15/20231,830,000 shares $1.31 million -0.5%N/A6.8 $0.72 3/31/20231,840,000 shares $1.80 million +0.6%2.9%6.4 $0.98 3/15/20231,830,000 shares $2.67 million No Change2.9%5.9 $1.46 2/28/20231,830,000 shares $2.75 million -0.5%2.9%5.6 $1.50 2/15/20231,840,000 shares $2.93 million -32.4%2.9%4.6 $1.59 1/31/20232,720,000 shares $4.35 million +70.0%N/A6.4 $1.60 1/15/20231,600,000 shares $2.40 million +0.6%N/A4.2 $1.50 12/30/20221,590,000 shares $1.65 million -4.2%N/A4.9 $1.04 12/15/20221,660,000 shares $1.63 million +0.6%N/A6.5 $0.98 11/30/20221,650,000 shares $1.61 million No ChangeN/A7.4 $0.98 11/15/20221,650,000 shares $1.61 million +1.9%N/A7.3 $0.98 10/31/20221,620,000 shares $1.80 million +14.1%N/A10 $1.11 10/15/20221,420,000 shares $1.42 million -4.7%2.3%8.4 $1.00 9/30/20221,490,000 shares $1.71 million +8.8%2.4%8 $1.15 9/15/20221,370,000 shares $1.89 million +5.4%2.2%6.8 $1.38Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.Click here to find out who they are. PIRS Short Interest - Frequently Asked Questions What is Pieris Pharmaceuticals' current short interest? Short interest is the volume of Pieris Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 12,800 shares of PIRS short. 1.12% of Pieris Pharmaceuticals' shares are currently sold short. Learn More on Pieris Pharmaceuticals' current short interest. What is a good short interest ratio for Pieris Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PIRS shares currently have a short interest ratio of 1.0. Learn More on Pieris Pharmaceuticals's short interest ratio. What is a good short interest percentage for Pieris Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.12% of Pieris Pharmaceuticals' floating shares are currently sold short. Is Pieris Pharmaceuticals' short interest increasing or decreasing? Pieris Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 12,800 shares, an increase of 4,166.7% from the previous total of 300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Pieris Pharmaceuticals' float size? Pieris Pharmaceuticals currently has issued a total of 1,240,000 shares. Some of Pieris Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pieris Pharmaceuticals currently has a public float of 1,140,000 shares. How does Pieris Pharmaceuticals' short interest compare to its competitors? 1.12% of Pieris Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Pieris Pharmaceuticals: Avalo Therapeutics, Inc. (10.13%), RedHill Biopharma Ltd. (2.38%), Monopar Therapeutics Inc. (1.24%), Kiora Pharmaceuticals, Inc. (0.56%), Purple Biotech Ltd (1.18%), FSD Pharma Inc. (1.00%), Edesa Biotech, Inc. (0.69%), Imunon, Inc. (3.95%), Elevai Labs, Inc. (0.48%), Akari Therapeutics, Plc (0.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Pieris Pharmaceuticals stock? Short selling PIRS is an investing strategy that aims to generate trading profit from Pieris Pharmaceuticals as its price is falling. PIRS shares are trading up $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Pieris Pharmaceuticals? A short squeeze for Pieris Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PIRS, which in turn drives the price of the stock up even further. How often is Pieris Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PIRS, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: AVTX Short Squeeze RDHL Short Squeeze MNPR Short Squeeze KPRX Short Squeeze PPBT Short Squeeze HUGE Short Squeeze EDSA Short Squeeze IMNN Short Squeeze ELAB Short Squeeze AKTX Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PIRS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersGold Set to EXPLODE!Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper